Homepage header image
Quest Diagnostics empowers people to take action to improve health outcomes.
Company Overview

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives.

Latest News
11102026

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on...

11092026

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a...

11092026

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a...

All Releases

Newsroom

Media Coverage
11132026
GenomeWeb
Quest has launched its AAVrh74 antibody ELISA companion diagnostic, which is authorized by the US Food and Drug Administration for identifying individuals with Duchenne muscular dystrophy who may be eligible for Sarepta’s gene therapy for the disease. The test, which is approved for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in human serum, is available through the Sarepta AAVrh74 antibody sponsored testing program.
11092026
NJBIZ
Amid growing public health concerns about environmental contaminants, Quest Diagnostics is expanding its focus on testing that can help consumers better understand their exposure to potentially harmful chemicals. Over the past two-and-a-half years, the Secaucus-based testing provider has unveiled one of the industry’s first consumer-accessible blood tests that can detect and measure per- and polyfluorinated alkyl substances (PFAS), as well as an expanded heavy metal blood and urine panels for determining levels of toxic elements like arsenic, cadmium, lead, mercury, cobalt and thallium.

All Coverage

Quest Diagnostics Health Trends™

Quest Diagnostics Health Trends™ is a series of reports from Quest Diagnostics on health conditions affecting a large number of Americans. Published in peer-reviewed journals, at scientific conferences and widely as a public service, the reports are designed to inform health care professionals, patients and policymakers about the status of the nation’s health.

 

See All

At A Glance...

Quest provides thousands of laboratory tests, ranging from advanced genomic tests for cancer and rare diseases to routine preventive tests for heart disease, diabetes and other chronic conditions. Our medical and scientific staff consists of over 700 M.D.s and Ph.Ds. We maintain approximately 7,700 patient access points, including approximately 2,000 Quest patient service centers, and a logistics team with over 4,000 courier vehicles and nearly 20 aircraft in the United States.

Media Resources

Journalists may contact Quest Diagnostics by emailing mediacontact@questdiagnostics.com

(opens in a new window)